{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:14:31Z","timestamp":1771262071521,"version":"3.50.1"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["POIG.01.01.02-00-069\/09"],"award-info":[{"award-number":["POIG.01.01.02-00-069\/09"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","award":["123-26924F"],"award-info":[{"award-number":["123-26924F"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jagiellonian Medical Research Centre Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.pharep.2015.05.022","type":"journal-article","created":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T04:10:00Z","timestamp":1433650200000},"page":"695-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacological modulation of fibrinolytic response \u2013 In vivo and in vitro studies"],"prefix":"10.1007","volume":"67","author":[{"given":"Karol","family":"Kramkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Leszczynska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlodzimierz","family":"Buczko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2015.05.022_bib0715","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7150\/ijbs.7502","article-title":"The vascular endothelium and human diseases","volume":"9","author":"Rajendran","year":"2013","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.pharep.2015.05.022_bib0720","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.thromres.2003.08.006","article-title":"Aspirin and the fibrinolytic response","volume":"110","author":"Buczko","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib0725","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.biologicals.2010.02.006","article-title":"Fibrinolysis standards: a review of the current status","volume":"38","author":"Thelwell","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.pharep.2015.05.022_bib0730","first-page":"35","article-title":"What drives \u201cfibrinolysis\u201d?","volume":"7","author":"Medcalf","year":"2015","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.pharep.2015.05.022_bib0735","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0740","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0090-6980(76)90047-2","article-title":"Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides","volume":"12","author":"Gryglewski","year":"1976","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharep.2015.05.022_bib0745","doi-asserted-by":"crossref","first-page":"19897","DOI":"10.1016\/S0021-9258(17)32104-X","article-title":"Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells","volume":"269","author":"Hara","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharep.2015.05.022_bib0750","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/01.CIR.90.4.1643","article-title":"Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system","volume":"90","author":"Nakagawa","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2015.05.022_bib0755","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0031-6989(78)80053-8","article-title":"Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men","volume":"10","author":"Szczeklik","year":"1978","journal-title":"Pharmacol Res Commun"},{"key":"10.1016\/j.pharep.2015.05.022_bib0760","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-4889(98)00041-X","article-title":"Prostaglandin I2 analog enhances the expression of urokinase-type plasminogen activator and wound healing","volume":"1403","author":"Hatane","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharep.2015.05.022_bib0765","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0049-3848(97)00255-7","article-title":"Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin","volume":"88","author":"Novacek","year":"1997","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib0770","first-page":"184","article-title":"In vitro analysis of synergistic effects of fibrinolytic agents and prostacyclin analogues","volume":"27","author":"Spiecker","year":"1997","journal-title":"Haemostasis"},{"key":"10.1016\/j.pharep.2015.05.022_bib0775","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2006-01-0094","article-title":"Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin","volume":"108","author":"Shariat-Madar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharep.2015.05.022_bib0780","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1246-7820(00)88980-6","article-title":"Vascular biosynthesis of nitric oxide: effect on hemostasis and fibrinolysis","volume":"6","author":"Schini-Kerth","year":"1999","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0785","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0790","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.freeradbiomed.2006.05.019","article-title":"Nitrite in nitric oxide biology: cause or consequence? A systems-based review","volume":"41","author":"Bryan","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharep.2015.05.022_bib0795","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-3565(25)32778-3","article-title":"Relationship between cyclic guanosine 39:59-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin","volume":"219","author":"Gruetter","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2015.05.022_bib0800","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.2174\/1381612033453785","article-title":"Bioactivity and pharmacological actions of carbon monoxide-releasing molecules","volume":"9","author":"Motterlini","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharep.2015.05.022_bib0805","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0076-6879(08)01218-4","article-title":"Interactive relations between nitric oxide (NO) and carbon monoxide (CO): heme oxygenase-1\/CO pathway is a key modulator in NO-mediated antiapoptosis and anti-inflammation","volume":"441","author":"Chung","year":"2008","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0810","doi-asserted-by":"crossref","first-page":"RE6","DOI":"10.1126\/stke.2302004re6","article-title":"Carbon monoxide: to boldly go where NO has gone before","volume":"2004","author":"Ryter","year":"2004","journal-title":"Sci STKE"},{"key":"10.1016\/j.pharep.2015.05.022_bib0815","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pharmthera.2009.05.005","article-title":"Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation \u2013 a tale of three gases!","volume":"123","author":"Li","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharep.2015.05.022_bib0820","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjp.0705825","article-title":"Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule","volume":"142","author":"Foresti","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2015.05.022_bib0825","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10557-012-6400-6","article-title":"Relaxant effect of a water soluble carbon monoxide-releasing molecule (CORM-3) on spontaneously hypertensive rat aortas","volume":"26","author":"Failli","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.pharep.2015.05.022_bib0830","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00210-012-0732-4","article-title":"Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors","volume":"385","author":"Chlopicki","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0835","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/ATVBAHA.112.253989","article-title":"Antithrombotic properties of water-soluble carbon monoxide-releasing molecules","volume":"32","author":"Kramkowski","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0840","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.thromres.2011.02.009","article-title":"Investigation into the mechanism(s) of antithrombotic effects of carbon monoxide releasing molecule-3 (CORM-3)","volume":"127","author":"Soni","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib0845","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/MBC.0b013e32833cea13","article-title":"The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent","volume":"21","author":"Nielsen","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.pharep.2015.05.022_bib0850","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MBC.0b013e32832f4335","article-title":"Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma","volume":"20","author":"Nielsen","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.pharep.2015.05.022_bib0855","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/15748847112079990050","article-title":"The therapeutic role of renin\u2013angiotensin system blockers in obesity-related renal disorders","volume":"9","author":"Santos","year":"2014","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0860","first-page":"529","article-title":"The physiological significance of the alternative pathways of angiotensin II production","volume":"57","author":"Kramkowski","year":"2006","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0865","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin\u2013angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J Intern Med"},{"issue":"Suppl. G","key":"10.1016\/j.pharep.2015.05.022_bib0870","first-page":"G9","article-title":"Fibrinolytic balance, the renin\u2013angiotensin system and atherosclerotic disease","volume":"19","author":"Vaughan","year":"1998","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pharep.2015.05.022_bib0875","first-page":"623","article-title":"Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor","volume":"60","author":"Buczko","year":"2008","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2015.05.022_bib0880","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.thromres.2012.11.001","article-title":"Aliskiren inhibits experimental venous thrombosis in two-kidney one-clip hypertensive rats","volume":"131","author":"Hermanowicz","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib0885","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharep.2014.08.021","article-title":"Impact of aliskiren on some hemostatic parameters in experimental arterial thrombosis in rats","volume":"67","author":"Hermanowicz","year":"2014","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2015.05.022_bib0890","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/BF03256921","article-title":"Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase","volume":"31","author":"Sica","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pharep.2015.05.022_bib0895","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0030-1263123","article-title":"Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome","volume":"42","author":"Fogari","year":"2010","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib0900","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/clpt.2011.356","article-title":"Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass","volume":"91","author":"Billings","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2015.05.022_bib0905","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00380-011-0204-7","article-title":"Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker","volume":"28","author":"Ishibashi","year":"2013","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharep.2015.05.022_bib0910","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1055\/s-0038-1656136","article-title":"Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells","volume":"77","author":"Nishimura","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib0915","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1160\/TH04-10-0701","article-title":"Angiotensin II enhances thrombosis development in renovascular hypertensive rats","volume":"93","author":"Mogielnicki","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib0920","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1055\/s-0037-1615041","article-title":"Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats","volume":"79","author":"Pawlak","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib0925","first-page":"251","article-title":"The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats","volume":"49","author":"Chabielska","year":"1998","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0930","first-page":"97","article-title":"Antithrombotic effect of captopril and enalapril in young rats","volume":"56","author":"Buczko","year":"2004","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0935","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.HYP.0000035396.27909.40","article-title":"Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1\u20137)","volume":"40","author":"Kucharewicz","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2015.05.022_bib0940","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1055\/s-0038-1656136","article-title":"Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells","volume":"77","author":"Masuda","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib0945","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.thromres.2005.05.014","article-title":"The effect of \u2018tissue\u2019 and \u2018plasma\u2019 angiotensin converting enzyme inhibitors on overall haemostatic potentials in rats","volume":"117","author":"Kramkowski","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib0950","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"European trial on reduction of cardiac events with Perindopril in stable coronary artery disease","volume":"362","author":"EUROPA Investigators","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2015.05.022_bib0955","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction, results of the survival and ventricular enlargement trial","volume":"327","author":"SAVE Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2015.05.022_bib0960","first-page":"145","article-title":"Prevention of heart failure in patients in the heart outcomes prevention evaluation study","volume":"342","author":"HOPE Investigators","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2015.05.022_bib0965","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1055\/s-0038-1656000","article-title":"Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin","volume":"77","author":"Brown","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib0970","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0002-9149(00)01200-5","article-title":"Inhibition of platelet aggregability by losartan in essential hypertension","volume":"86","author":"Levy","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0975","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0090-6980(92)90070-A","article-title":"DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2\/prostaglandin H2 (TP) receptors","volume":"44","author":"Liu","year":"1992","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharep.2015.05.022_bib0980","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(24)35282-6","article-title":"Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation","volume":"292","author":"Li","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2015.05.022_bib0985","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00005344-199808000-00005","article-title":"Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats","volume":"32","author":"Li","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib0990","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00004872-199917030-00019","article-title":"Effect of losartan on human platelet activation","volume":"17","author":"Guerra-Cuesta","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharep.2015.05.022_bib0995","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/00005344-200006000-00012","article-title":"Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation","volume":"35","author":"Monton","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1000","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1012750430056","article-title":"Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling","volume":"15","author":"Schwemmer","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharep.2015.05.022_bib1005","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.HYP.28.6.967","article-title":"Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors","volume":"28","author":"Maeso","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2015.05.022_bib1010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/01.HYP.31.1.349","article-title":"AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism","volume":"31","author":"Gohlke","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2015.05.022_bib1015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1161\/01.HYP.0000034745.98129.EC","article-title":"Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release","volume":"40","author":"Kalinowski","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2015.05.022_bib1020","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0735-1097(03)00846-5","article-title":"Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients","volume":"42","author":"Koh","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2004.07.008","article-title":"Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study","volume":"177","author":"Koh","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharep.2015.05.022_bib1030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3317\/jraas.2000.036","article-title":"The renin\u2013angiotensin\u2013aldosterone system and fibrinolysis","volume":"1","author":"Felmeden","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharep.2015.05.022_bib1035","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/bjp.2008.200","article-title":"Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin","volume":"154","author":"Xavier","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1040","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1160\/TH07-03-0237","article-title":"Acute aldosterone infusion enhances thrombosis development in normotensive rats","volume":"98","author":"Stankiewicz","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib1045","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1470320310397405","article-title":"Study of the mechanisms of aldosterone prothrombotic effect in rats","volume":"12","author":"Gromotowicz","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharep.2015.05.022_bib1050","article-title":"Eplerenone reduces arterial thrombosis in diabetic rats","author":"Zakrzeska","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharep.2015.05.022_bib1055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4093\/dmj.2012.36.2.128","article-title":"Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats","volume":"36","author":"Ahn","year":"2012","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.pharep.2015.05.022_bib1060","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality, CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2015.05.022_bib1065","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/01.CIR.98.15.1510","article-title":"Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart)","volume":"98","author":"Nolan","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2015.05.022_bib1070","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1067\/mhj.2002.130300","article-title":"Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase","volume":"144","author":"Istvan","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharep.2015.05.022_bib1075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","article-title":"Isoprenoids as mediators of the biological effects of statins","volume":"110","author":"Liao","year":"2002","journal-title":"J Clin Investig"},{"key":"10.1016\/j.pharep.2015.05.022_bib1080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1085","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1160\/TH04-02-0064","article-title":"New nonlipid effects of statins and their clinical relevance in cardiovascular disease","volume":"91","author":"Undas","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib1090","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2165\/00003495-200363170-00005","article-title":"Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes","volume":"63","author":"Krysiak","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2015.05.022_bib1095","first-page":"001","article-title":"Effects on plasma fibrinogen levels and fibrinolysis","volume":"S6","author":"Cappelletti","year":"2012","journal-title":"J Nutr Disorders Ther"},{"key":"10.1016\/j.pharep.2015.05.022_bib1100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-0037-1613968","article-title":"Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells","volume":"84","author":"Mussoni","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib1105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jcb.10602","article-title":"Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells","volume":"90","author":"Markle","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharep.2015.05.022_bib1110","first-page":"209","article-title":"Lipid-independent effects of an estrogen\u2013statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor-I in human endothelial cell cultures","volume":"4","author":"Seeger","year":"2001","journal-title":"Climacteric"},{"key":"10.1016\/j.pharep.2015.05.022_bib1115","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2362.2002.01086.x","article-title":"Time-dependent effect of statins on platelet function in hypercholesterolaemia","volume":"32","author":"Puccetti","year":"2002","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.pharep.2015.05.022_bib1120","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/01.ATV.18.10.1643","article-title":"Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys","volume":"18","author":"Hale","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1125","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.pharep.2015.05.022_bib1130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0049-3848(99)00037-7","article-title":"Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA reductase inhibitor","volume":"95","author":"Huhle","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib1135","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.ATV.15.6.759","article-title":"Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia, Effects of pravastatin","volume":"15","author":"Le Quan Sang","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1042\/CS20030148","article-title":"Statins and their role in vascular protection","volume":"105","author":"Mason","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharep.2015.05.022_bib1145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cardiores.2004.10.018","article-title":"Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury","volume":"65","author":"Birnbaum","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib1150","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00380-010-0097-x","article-title":"Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide","volume":"26","author":"Skogastierna","year":"2011","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharep.2015.05.022_bib1155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0038-1650023","article-title":"On the regulation and control of fibrinolysis, Edward Kowalski Memorial Lecture","volume":"43","author":"Collen","year":"1980","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib1160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-2007-1004407","article-title":"Physiologic and pharmacologic enhancement of fibrinolysis","volume":"10","author":"Prowse","year":"1984","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib1165","first-page":"51","article-title":"Thrombolytic activity of beta-adrenolytic drug, sotalol","volume":"49","author":"Korbut","year":"1998","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0014-2999(81)90077-7","article-title":"Propranolol and sotalol augment the coronary vasodilatory action of prostacyclin (PGI2) in rabbit isolated hearts","volume":"75","author":"Gillespie","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1175","first-page":"909","article-title":"Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol","volume":"5","author":"Gonz\u00e1lez Maqueda","year":"1994","journal-title":"Coron Artery Dis"},{"issue":"5 Suppl.","key":"10.1016\/j.pharep.2015.05.022_bib1180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/03331024860060S504","article-title":"Beta-adrenoceptor blockade, platelets, and rheologic factors","volume":"6","author":"Winther","year":"1986","journal-title":"Cephalalgia"},{"issue":"Suppl. 3","key":"10.1016\/j.pharep.2015.05.022_bib1185","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00005344-199106183-00011","article-title":"Does antihypertensive therapy affect the natural protection against thrombosis?","volume":"18","author":"Gleerup","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1190","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0828-282X(07)70227-1","article-title":"The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients","volume":"23","author":"Tarighi","year":"2007","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1195","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijcard.2006.03.046","article-title":"Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol","volume":"116","author":"Celik","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1200","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1753944709104496","article-title":"Nitric oxide mechanisms of nebivolol","volume":"3","author":"Maffei","year":"2009","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.pharep.2015.05.022_bib1205","first-page":"20","article-title":"Carvedilol\u2014a beta-blocker with considerable antiaggregatory effect on human blood platelets","volume":"106","author":"Petrikova","year":"2005","journal-title":"Bratisl Lek Listy"},{"key":"10.1016\/j.pharep.2015.05.022_bib1210","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.amjhyper.2005.11.011","article-title":"Carvedilol action is dependent on endogenous production of nitric oxide","volume":"19","author":"Afonso","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharep.2015.05.022_bib1215","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2146\/ajhp120383","article-title":"Probable carvedilol-induced thrombocytopenia","volume":"70","author":"Alex","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.pharep.2015.05.022_bib1220","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00265838","article-title":"Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol","volume":"40","author":"Jansson","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1225","first-page":"3","article-title":"Prostacyclin among prostanoids","volume":"60","author":"Gryglewski","year":"2008","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2015.05.022_bib1230","first-page":"563","article-title":"Dihydropyridine calcium antagonists are associated with increased albuminuria in treatment-resistant hypertensives","volume":"23","author":"Hummel","year":"2010","journal-title":"J Nephrol"},{"issue":"4 Suppl.","key":"10.1016\/j.pharep.2015.05.022_bib1235","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199322004-00002","article-title":"The role of endothelium in cardiovascular homeostasis and diseases","volume":"22","author":"Rubanyi","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.HYP.31.1.321","article-title":"Relationship between endothelial function and fibrinolysis in early hypertension","volume":"31","author":"Tomiyama","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2015.05.022_bib1245","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0049-3848(88)90233-2","article-title":"Effects of verapamil, diltiazem and nifedipine on some parameters of hemostasis in the rat","volume":"50","author":"Pietraszek","year":"1988","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib1250","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3748\/wjg.v12.i15.2351","article-title":"Effect of verapamil on nitric oxide synthase in a portal vein-ligated rat model: role of prostaglandin","volume":"12","author":"Lay","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1255","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/10641963.2012.702833","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI) levels in hypertensive patients and a comparison of the effects of amlodipine and ramipril on TAFI levels","volume":"35","author":"Ozkan","year":"2013","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharep.2015.05.022_bib1260","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.bjp.0707383","article-title":"1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2\/prostacyclin pathway","volume":"152","author":"Chlopicki","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1265","first-page":"515","article-title":"N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats","volume":"58","author":"Mogielnicki","year":"2007","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1270","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.2042-7158.1966.tb07909.x","article-title":"The fibrinolytic activity of anti-inflammatory drugs","volume":"18","author":"Gryglewski","year":"1966","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1275","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(70)90747-6","article-title":"Aspirin and blood fibrinolysis","volume":"1","author":"Menon","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2015.05.022_bib1280","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM197703102961001","article-title":"Increased blood fibrinolytic activity after aspirin ingestion","volume":"296","author":"Moroz","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2015.05.022_bib1285","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/BF01939014","article-title":"The effect of salicylates on plasma fibrinolytic activity in the rat","volume":"30","author":"Rosenior","year":"1974","journal-title":"Experientia"},{"key":"10.1016\/j.pharep.2015.05.022_bib1290","first-page":"412","article-title":"Fibrinolysis in the rat after short-term aspirin therapy","volume":"38","author":"Housholder","year":"1980","journal-title":"J Oral Surg"},{"key":"10.1016\/j.pharep.2015.05.022_bib1295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0022-3565(25)21331-3","article-title":"Aspirin acetylates fibrinogen and enhances fibrinolysis, fibrinolytic effect is independent of changes in plasminogen activator levels","volume":"250","author":"Bjornsson","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2015.05.022_bib1300","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.STR.24.6.801","article-title":"Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication","volume":"24","author":"Tohgi","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.pharep.2015.05.022_bib1305","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/0002-9378(95)90031-4","article-title":"Effect of low-dose aspirin during pregnancy on fibrinolytic variables before and after parturition","volume":"172","author":"Bremer","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1310","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1053\/euhj.1998.1088","article-title":"Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid","volume":"19","author":"Williams","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharep.2015.05.022_bib1315","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.thromres.2005.02.007","article-title":"Marked increase of fibrin gel permeability with very low dose ASA treatment","volume":"116","author":"Antovic","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib1320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2012.03.154","article-title":"Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labelling study","volume":"421","author":"Svensson","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharep.2015.05.022_bib1325","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00001721-199512000-00004","article-title":"The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator","volume":"6","author":"Williams","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.pharep.2015.05.022_bib1330","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI111454","article-title":"Aspirin inhibits vascular plasminogen activator activity in vivo, studies utilizing a new assay to quantify plasminogen activator activity","volume":"74","author":"Levin","year":"1984","journal-title":"J Clin Investig"},{"key":"10.1016\/j.pharep.2015.05.022_bib1335","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1016\/0006-2952(86)90400-4","article-title":"Low dose aspirin does not prevent fibrinolytic response to venous occlusion","volume":"35","author":"deGaetano","year":"1986","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharep.2015.05.022_bib1340","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0049-3848(87)90140-X","article-title":"Aspirin effect on platelet antiplasmins release","volume":"47","author":"Woods","year":"1987","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib1345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0049-3848(88)90090-4","article-title":"Aspirin effect on the release of plasminogen activator inhibitors by human platelets","volume":"52","author":"Woods","year":"1988","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2015.05.022_bib1350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF02877557","article-title":"Acetylsalicylic acid inhibits platelet PAI-1 antigen release without affecting circulating PAI-1 antigen in plasma","volume":"20","author":"Cogo","year":"1990","journal-title":"Ric Clin Lab"},{"key":"10.1016\/j.pharep.2015.05.022_bib1355","first-page":"669","article-title":"Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers","volume":"56","author":"Raschka","year":"2001","journal-title":"Therapie"},{"key":"10.1016\/j.pharep.2015.05.022_bib1360","first-page":"895","article-title":"Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys","volume":"46","author":"Lehmann","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharep.2015.05.022_bib1365","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm782","article-title":"Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse","volume":"8","author":"Falati","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pharep.2015.05.022_bib1370","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.20021868","article-title":"Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin","volume":"197","author":"Falati","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharep.2015.05.022_bib1375","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2005-04-1512","article-title":"Platelet PECAM-1 inhibits thrombus formation in vivo","volume":"107","author":"Falati","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharep.2015.05.022_bib1380","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2011-08-372532","article-title":"Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of \u03b23 integrins","volume":"120","author":"Cho","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharep.2015.05.022_bib1385","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1182\/blood-2005-09-3687","article-title":"Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo","volume":"107","author":"Dubois","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharep.2015.05.022_bib1390","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1084\/jem.190.12.1769","article-title":"Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration","volume":"190","author":"Yang","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharep.2015.05.022_bib1395","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood-2010-05-283986","article-title":"Laser-induced endothelial cell activation supports fibrin formation","volume":"116","author":"Atkinson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharep.2015.05.022_bib1400","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00424-008-0466-9","article-title":"Real-time analysis of platelet aggregation and procoagulant activity during thrombus formation in vivo","volume":"456","author":"Hayashi","year":"2008","journal-title":"Pfl\u00fcgers Arch"},{"issue":"Suppl. 1","key":"10.1016\/j.pharep.2015.05.022_bib1405","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1538-7836.2007.02482.x","article-title":"In vivo thrombus formation","volume":"5","author":"Furie","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharep.2015.05.022_bib1410","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1172\/JCI26987","article-title":"Thrombus formation in vivo","volume":"115","author":"Furie","year":"2005","journal-title":"J Clin Investig"},{"key":"10.1016\/j.pharep.2015.05.022_bib1415","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1007\/s00018-005-5099-y","article-title":"Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction","volume":"62","author":"Wolfs","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharep.2015.05.022_bib1420","doi-asserted-by":"crossref","first-page":"e55466","DOI":"10.1371\/journal.pone.0055466","article-title":"Binding of thrombin-activated platelets to a fibrin scaffold through \u03b1(IIb)\u03b23 evokes phosphatidylserine exposure on their cell surface","volume":"8","author":"Brzoska","year":"2013","journal-title":"PLOS ONE"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:08Z","timestamp":1752611768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2015.05.022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1734114015001097"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2015.05.022","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological modulation of fibrinolytic response \u2013 In vivo and in vitro studies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2015.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}